APA (7th ed.) Citation

Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., . . . Varmus, H. E. (2005). KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib. PLoS medicine, 2(1), e17. https://doi.org/10.1371/journal.pmed.0020017

Chicago Style (17th ed.) Citation

Pao, William, et al. "KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib." PLoS Medicine 2, no. 1 (2005): e17. https://doi.org/10.1371/journal.pmed.0020017.

MLA (9th ed.) Citation

Pao, William, et al. "KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib." PLoS Medicine, vol. 2, no. 1, 2005, p. e17, https://doi.org/10.1371/journal.pmed.0020017.